Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ENERGIF-703 by Energenesis Biomedical for Diabetic Foot Ulcers: Likelihood of Approval
ENERGIF-703 is under clinical development by Energenesis Biomedical and currently in Phase III for Diabetic Foot Ulcers. According to GlobalData,...